Drug
610
610 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting1
unknown1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
recruiting133%
unknown133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
active_not_recruitingphase_2
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
NCT06680947
recruitingphase_3
Efficacy and Safety Study of 610 in Patients With Severe Asthma
NCT06323213
unknownphase_1
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
NCT04445038
Clinical Trials (3)
Showing 3 of 3 trials
NCT06680947Phase 2
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
NCT06323213Phase 3
Efficacy and Safety Study of 610 in Patients With Severe Asthma
NCT04445038Phase 1
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3